Commentary on: Treatment of HCV infection in chronic kidney disease Alavian

Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi

Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis Fabrizio Fabrizi, Roberta Cerutti, Vivek Dixit, Ezequiel Ridruejo